Ulcerative colitis is a common condition, resulting from a complex interplay between environmental, genetic and microbial factors, and dysregulated immune response leading to chronic intestinal ...

In the interim, progress in our understanding of facets of the pathophysiology of inflammatory bowel disease has led to the development of useful new therapies. The Center for the Study of ...

Thus, focusing on the ability of this model to portray UC pathophysiology, the research team next tested the effects of a commonly used drug for treating UC, tofacitinib, in IBD-like colonic ...

In recent decades, there have been significant advances in the understanding of IBD pathophysiology and the development of new treatments. The International Organization for the Study of ...

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 pathway ...

Iterative Scopes and Eli Lilly reached a partnership Feb. 11 to conduct research around how artificial intelligence can improve understanding of inflammatory bowel disease pathophysiology and target ...

TREM-1 has been reported as a likely contributor to IBD pathophysiology, and targeting this biological pathway could offer a new treatment option for IBD patients with immune dysregulation.

Pathophysiology of Ulcerative Colitis As the name suggests, UC is indeed an inflammatory disorder in the colon. Inflammation is most typically found in the rectum but it can extend proximally to ...

Inflammatory bowel disease (IBD) causes various gastrointestinal issues, including diarrhea, because inflammation causes damage to the mucus lining of the digestive tract. Symptoms and their ...

Ulcerative colitis (UC) can send you to the bathroom. A lot. In fact, diarrhea is one of the most common symptoms of UC. But some people have the opposite problem. If you have UC with constipation ...